Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness

Journal of Infectious Diseases

Volumn 213, Issue 8, 2016, Pages 1216-1223

  Omer, Saad B ^a,b,c,e   Phadke, Varun K ^d   Bednarczyk, Robert A ^a,e   Chamberlain, Allison T ^b   Brosseau, Jennifer L ^b   Orenstein, Walter A ^a,c,e  

^a Hubert Department of Global Health   (United States)

^b EMORY UNIVERSITY   (United States)

^c Department of Pediatrics ^*  (United States)

^d Shimane University School of Medicine   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

inflammation; influenza; medically attended acute respiratory illness; statin; vaccine effectiveness

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; ANTIINFLAMMATORY AGENT;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICALLY ATTENDED ACUTE RESPIRATORY ILLNESS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; VACCINATION; ACUTE DISEASE; DRUG INTERACTION; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS;

ACUTE DISEASE; AGED; ANTI-INFLAMMATORY AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84965133926     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv457     Document Type: Article

References (47)

1. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013; 310:2451-2.
2. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360:7-22.
3. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-59.
4. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011; 22:165-70.
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
6. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J M 2005; 352:20-8.
7. Kruger P, Bailey M, Bellomo R, et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013; 187:743-50.
8. Liappis AP, Kan VL, Rochester CG, Simon GL. the effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33:1352-7.
9. Nielsen AG, Nielsen RB, Riis AH, Johnsen SP, Sorensen HT, Thomsen RW. the impact of statin use on pneumonia risk and outcome: A combined populationbased case-control and cohort study. Crit Care 2012; 16:R122.
10. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. J Infect Dis 2012; 205:13-9.
11. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339-50.
12. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006; 45:106-11.
13. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res 2014; 66:1016-26.
14. Kubiet MA, Gonzalez-Rothi RJ, Cottey R, Bender BS. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996; 110:367-70.
15. Lee PY, Scumpia PO, Byars JA, et al. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine 2006; 24:4035-40.
16. Packard RRS, Schlegel S, Senouf D, et al. Atorvastatin treatment and vaccination efficacy. J Clin Pharmacol 2007; 47:1022-7.
17. Flu activity in Georgia. Available at: https://dph.georgia.gov/flu-activity-georgia.
18. Klein SL, Jedlicka A, Pekosz A. the Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 10:338-49.
19. Altman DG, Bland JM. Interaction revisited: The difference between two estimates. BMJ 2003; 326:219.
20. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 2010; 28:7267-72.
21. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003; 158:305-11.
22. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: The PRISMA study. Arch Intern Med 2005; 165:274-80.
23. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59:572-82.
24. Engler RJ, Nelson MR, Klote MM, et al. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405-14.
25. Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005; 111:1439-47.
26. Ghittoni R, Napolitani G, Benati D, et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 2006; 36:2885-93.
27. Bessler H, Salman H, Bergman M, Straussberg R, Djaldetti M. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin Immunol 2005; 117:73-7.
28. Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005; 19:605-7.
29. Youssef S, Stuve O, Patarroyo JC, et al. the HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78-84.
30. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol 2010; 264:71-7.
31. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205.
32. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99:417-35.
33. Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 2010; 138:1281-8.
34. Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: A cohort study. PLoS One 2009; 4:e8087.
35. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011; 6:e18120.
36. King JC Jr, Lichenstein R, Magder LS. Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. Vaccine 2013; 31:839-44.
37. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005; 23:1540-8.
38. Lichenstein R, Magder LS, King RE, King JC Jr. the relationship between influenza outbreaks and acute ischemic heart disease in Maryland residents over a 7-year period. J Infect Dis 2012; 206:821-7.
39. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166:348-54.
40. Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med 2014; 174:1038-45.
41. Kim YH, Kim JK, Kim DJ, et al. Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model. J Infect Dis 2012; 205:244-51.
42. Park HL, Shim SH, Lee EY, et al. Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. Hum Vaccin Immunotherapeutics 2014; 10:1181-6.
43. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes 2012; 36: 1072-7.
44. Campitelli MA, Rosella LC, Kwong JC. the association between obesity and outpatient visits for acute respiratory infections in Ontario, Canada. Int J Obes 2014; 38:113-9.
45. Biggerstaff M, Jhung MA, Reed C, Fry AM, Balluz L, Finelli L. Influenzalike illness, the time to seek healthcare, and influenza antiviral receipt during the 2010-2011 influenza season-United States. J Infect Dis 2014; 210:535-44.
46. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9.
47. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.